Molecule
Alemtuzumab is a CD52-directed cytolytic antibody indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). It is available as injection for intravenous use. MedsAcross supplies Alemtuzumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
CAMPATH is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). CAMPATH is a CD52-directed cytolytic antibody indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL).
Source: US FDA prescribing information
CAMPATH binds to CD52, an antigen present on the surface of B and T lymphocytes, a majority of monocytes, macrophages, NK cells, and a subpopulation of granulocytes. A proportion of bone marrow cells, including some CD34+ cells, express variable levels of CD52. The proposed mechanism of action is antibody-dependent cellular-mediated lysis following cell surface binding of CAMPATH to the leukemic cells.
Source: US FDA prescribing information
Administer as an intravenous infusion over 2 hours. Escalate to recommended dose of 30 mg/day three times per week for 12 weeks. Premedicate with oral antihistamine and acetaminophen.
Source: US FDA prescribing information
None. None
Source: US FDA prescribing information
Boxed warning (cytopenias, infusion-related reactions, and infections warning: cytopenias, infusion-related reactions, and infections): Serious, including fatal, cytopenias, infusion-related reactions, and infections can occur (5.1–5.3). Limit doses to 30 mg (single) and 90 mg (cumulative weekly), higher doses increase risk of pancytopenia. Escalate dose gradually and monitor patients during infusion. Cytopenias: Obtain complete blood counts (CBC) and platelet counts at weekly intervals during therapy and CD4 counts after therapy until recovery to ≥200 cells/µL. Withhold for severe cytopenias. Discontinue for autoimmune or severe hematologic adverse reactions. Immunosuppression/Infections: CAMPATH induces severe and prolonged lymphopenia and increases risk of infection. If a serious infection occurs, withhold treatment until infection resolves.
Source: US FDA prescribing information
The following clinically significant adverse reactions are discussed in greater detail in other sections of the label: Cytopenias Infusion-Related Reactions Immunosuppression/Infections Most common adverse reactions (≥10%): cytopenias, infusion-related reactions, cytomegalovirus (CMV) and other infections, nausea, emesis, diarrhea, and insomnia.
Source: US FDA prescribing information
No formal drug interaction studies have been performed with CAMPATH.
Source: US FDA prescribing information
Store CAMPATH at 2°C to 8°C (36°F to 46°F). Do not freeze. If accidentally frozen, thaw at 2°C to 8°C before administration. Protect from direct sunlight.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Alemtuzumab, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Campath 30 mg/1 mL injectionIntravenous Cold chain | Genzyme | US FDA | Available on request |
| Lemtrada 12 mg/1.2 mL injectionIntravenous Cold chain | Genzyme | US FDA | Available on request |
2 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Alemtuzumab in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 2 presentations of Alemtuzumab and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Alemtuzumab, including Campath, Lemtrada.
Yes. The US FDA first approved Alemtuzumab on 7 May 2001, according to Drugs@FDA.
Yes. Alemtuzumab has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Alemtuzumab must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Alemtuzumab is classified under ATC code L01XC04 (Alemtuzumab).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.